Ann Xi
YOU?
Author Swipe
View article: SAT-811 Characterizing Patients With Thyroid Eye Disease Initiating Treatment With Teprotumumab: A Retrospective Cohort Study Using Linked Academy IRIS® Registry And Komodo Claims Data
SAT-811 Characterizing Patients With Thyroid Eye Disease Initiating Treatment With Teprotumumab: A Retrospective Cohort Study Using Linked Academy IRIS® Registry And Komodo Claims Data Open
Disclosure: L. Mawn: Amgen Inc, Genentech, Inc. E.M. Shriver: Amgen Inc, Genentech, Inc. M. Tamhankar: Amgen Inc, Genentech, Inc., Viridian Therapeutics, argenx. Y. Yuan: Amgen Inc. A. Xi: Amgen Inc. J. Ayala-Haedo: Amgen Inc. H. Patel: Am…
View article: Clinical and data-driven optimization of Genomiser for rare disease patients: experience from the Hong Kong Genome Project
Clinical and data-driven optimization of Genomiser for rare disease patients: experience from the Hong Kong Genome Project Open
Genomiser is a phenotype-driven tool that prioritizes coding and non-coding variants by relevance in rare disease diagnosis; yet comprehensive evaluation of its performance on real-life whole genome sequencing data is lacking. The Hong Kon…
View article: Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison
Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison Open
Context Teprotumumab and/or intravenous methylprednisolone (IVMP) are first-line treatments for thyroid eye disease (TED)/Graves’ orbitopathy. Direct comparisons of these treatments on Graves’ Orbitopathy Quality of Life Questionnaire (GO-…
View article: Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs
Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs Open
Ruxolitinib is associated with reduced HCRU and direct costs of medical care in addition to increased survival, suggesting it to be a cost-effective advance for patients with MF.
View article: Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population
Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population Open
Sanjay Sethi,1 Barry J Make,2 Scott B Robinson,3 Shambhavi Kumar,3 Michael Pollack,4 Chad Moretz,5 Jill Dreyfus,5 Ann Xi,5 Dakota Powell,5 Norbert Feigler4 1University at Buffalo, Buffalo, NY, USA; 2National Jewish Health, Denver, CO, USA;…
View article: Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia
Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia Open
Patients with polycythemia vera (PV) and essential thrombocythemia (ET) have increased thrombotic risk. This retrospective, real-world analysis of Medicare patients (age ≥ 65 years) newly diagnosed with high-risk PV or intermediate-/high-r…
View article: Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval
Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval Open
View article: PRS7 Characteristics, Cost and Health Care Resource Use in a Population of Medicare Fee-for-Service (FFS) Patients with Chronic Obstructive Pulmonary Disease (COPD) Who Also Experience Pneumonia
PRS7 Characteristics, Cost and Health Care Resource Use in a Population of Medicare Fee-for-Service (FFS) Patients with Chronic Obstructive Pulmonary Disease (COPD) Who Also Experience Pneumonia Open
View article: Does Baseline Exacerbation History in COPD Predict Future Exacerbation Frequency? Real World Insights from Multiple US Insurers
Does Baseline Exacerbation History in COPD Predict Future Exacerbation Frequency? Real World Insights from Multiple US Insurers Open
View article: <p>Incremental Costs Associated with Length of Hospitalization Due to Viral Pneumonia: Impact of Intensive Care and Economic Implications of Reducing the Length of Stay in the Era of COVID-19</p>
Incremental Costs Associated with Length of Hospitalization Due to Viral Pneumonia: Impact of Intensive Care and Economic Implications of Reducing the Length of Stay in the Era of COVID-19 Open
The incremental daily cost of a hospitalization is substantial for US patients with commercial insurance and for Medicare patients. These findings may help quantify the economic value of COVID-19 treatments that reduce LOS.
View article: DESCRIPTIVE REAL-WORLD PAYER COMPARISONS OF EXACERBATION FREQUENCY AND HEALTHCARE RESOURCE UTILIZATION AFTER COPD DIAGNOSIS
DESCRIPTIVE REAL-WORLD PAYER COMPARISONS OF EXACERBATION FREQUENCY AND HEALTHCARE RESOURCE UTILIZATION AFTER COPD DIAGNOSIS Open